Startup led by former Seagen CEO Clay Siegall merges with public company in $125M deal Morphimmune, a biotech company led by former Seagen CEO Clay Siegall, is merging with a public biotech company, Immunome, in… Read More
Q&A with Seagen founder Clay Siegall on the Pfizer deal and his new biotech startup Clay Siegall is proud of his legacy as co-founder and longtime CEO of Seagen, the largest biotech company in the… Read More
Seagen founder Clay Siegall is back in biotech as CEO of Purdue University spinout Seagen founder Clay Siegall is jumping back into the biotech world as CEO and president of Morphimmune. Founded in 2020,… Read More
